← Leaderboards
Sunil Parikh
University Of California San Francisco
$7,693,164
Attributed
$13,065,806
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,551,081 · 8
By mechanism
R01$7,257,543 · 1
U01$3,487,742 · 1
R21$1,713,021 · 4
U19$1,485,275 · 1
K23$607,500 · 1
Top collaborators
- Francesca T. Aweeka15 shared
- Brian David Foy9 shared
- Roch Kounbobr Dabire4 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Matthew G Dorsey$21,862,621
- Francesca T. Aweeka$9,163,452
- Heidi A Hopkins$364,710
- Thomas M Lietman$24,360,475
- Jay Z Parrish$4,520,210
Others in their field
Top investigators on “Malaria”
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
MalariaPharmaceutical PreparationsInfectionResistanceParasitesAfricaChildCombined Modality TherapyArtemisininsDrug ResistanceBaseDoseDrug KineticsAntimalarialsPregnant WomenUgandaBenflumetolPharmacodynamicsFollow-UpChildhoodMalaria TransmissionAntiretroviral TherapyArtemetherDrug Exposure
Grant awards (37)
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$656,987
R01 · FY2025 · HD · contact PI
Burkina Faso ICEMR$330,847
U19 · FY2025 · AI
Burkina Faso ICEMR$245,008
U19 · FY2025 · AI
Burkina Faso ICEMR$166,784
U19 · FY2025 · AI
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$129,641
R01 · FY2025 · HD · contact PI
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$79,308
R01 · FY2025 · HD · contact PI
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa$930,846
R01 · FY2024 · HD · contact PI
Burkina Faso ICEMR$742,636
U19 · FY2024 · AI
Delineating host, parasite and pharmacologic factors impacting the treatment of malaria in children with and without HIV$198,714
R21 · FY2023 · HD · contact PI
Non-invasive detection of malaria parasites in vitro and in Cameroonian adults$194,357
R21 · FY2023 · AI · contact PI
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria$674,640
U01 · FY2022 · AI
Non-invasive detection of malaria parasites in vitro and in Cameroonian adults$245,063
R21 · FY2022 · AI · contact PI
Delineating host, parasite and pharmacologic factors impacting the treatment of malaria in children with and without HIV$243,130
R21 · FY2022 · HD · contact PI
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria$678,222
U01 · FY2021 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$47,014
R01 · FY2021 · HD
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria$684,788
U01 · FY2020 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$540,524
R01 · FY2020 · HD
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria$704,319
U01 · FY2019 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$540,524
R01 · FY2019 · HD
TRANSMIT: Tracking Antimalarial Resistance in Mosquito Populations$245,945
R21 · FY2019 · AI · contact PI
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria$745,773
U01 · FY2018 · AI
Optimizing ACT use for African children in the setting of HIV and malnutrition$546,801
R01 · FY2018 · HD
TRANSMIT: Tracking Antimalarial Resistance in Mosquito Populations$204,005
R21 · FY2018 · AI · contact PI
Optimizing ACT use for African children in the setting of HIV and malnutrition$560,173
R01 · FY2017 · HD
Optimizing ACT use for African children in the setting of HIV and malnutrition$597,359
R01 · FY2016 · HD
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$503,880
R01 · FY2015 · HD
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$512,768
R01 · FY2014 · HD
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$496,716
R01 · FY2013 · HD
Innate Immune Responses in Populations with Differing Susceptibility to Malaria$159,682
R21 · FY2013 · AI · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$535,652
R01 · FY2012 · HD
Innate Immune Responses in Populations with Differing Susceptibility to Malaria$222,125
R21 · FY2012 · AI · contact PI
Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda$579,350
R01 · FY2011 · HD
Host Polymorphisms and Uncomplicated Malaria$121,500
K23 · FY2008 · AI · contact PI
Host Polymorphisms and Uncomplicated Malaria$121,500
K23 · FY2007 · AI · contact PI
Host Polymorphisms and Uncomplicated Malaria$121,500
K23 · FY2006 · AI · contact PI
Host Polymorphisms and Uncomplicated Malaria$121,500
K23 · FY2005 · AI
Host Polymorphisms and Uncomplicated Malaria$121,500
K23 · FY2004 · AI